Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

Schöffski, P, Wozniak, A, Stacchiotti, S et al. (20 more authors) (2017) Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’. Annals of Oncology, 28 (12). pp. 3000-3008. ISSN 0923-7534

Abstract

Metadata

Authors/Creators:
  • Schöffski, P
  • Wozniak, A
  • Stacchiotti, S
  • Rutkowski, P
  • Blay, J-Y
  • Lindner, LH
  • Strauss, SJ
  • Anthoney, A
  • Duffaud, F
  • Richter, S
  • Grünwald, V
  • Leahy, MG
  • Reichardt, P
  • Sufliarsky, J
  • van der Graaf, WT
  • Sciot, R
  • Debiec-Rychter, M
  • van Cann, T
  • Marréaud, S
  • Lia, M
  • Raveloarivahy, T
  • Collette, L
  • Bauer, S
Keywords: clear-cell sarcoma, MET gene, EWSR1 gene rearrangement, tyrosine kinase inhibitor, crizotinib
Dates:
  • Published: 1 December 2017
  • Published (online): 18 September 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 30 Oct 2019 16:49
Last Modified: 30 Oct 2019 16:49
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/annonc/mdx527
Related URLs:

Commentary/Response Threads

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics